The Standard Side-Effect List Is Sorted by Severity. The Mushroom Is Sorted by Receptor.
Almost every page on Amanita muscaria side effects presents the same two-column layout. Low dose: mild nausea, dizziness, increased salivation, drowsiness. Higher dose: confusion, disorientation, muscle twitching, heavy sedation. Read that way, it looks like a severity gradient — the second column is the first column turned up.
It isn't. Sorted by mechanism instead of by severity, that single list resolves into three separate pharmacologies acting on three different systems, and the items don't sit in the order the layout implies. Muscle twitching is not a stronger version of drowsiness; it comes from a compound that does the opposite thing. Salivation isn't an early warning of sedation; it belongs to a system neither of the mushroom's two famous compounds acts on. And the reason effects arrive in a rough sequence, and sometimes swing back and forth, is chemistry with a timeline rather than dose with a dial.
This article is about that structure — which receptor produces which symptom, in what order, and why. It deliberately does not re-cover the poison-centre data, FDA findings and product testing handled in our piece on what the Amanita adverse-event record actually contains. This one is the pharmacology underneath those reports.
Two Compounds, Pointing in Opposite Directions
The starting fact is well established and rarely spelled out on consumer pages. A. muscaria's principal active constituents are ibotenic acid and muscimol, and they act on the two great opposing neurotransmitter systems in the brain. The IPCS poisons information monograph puts it plainly: "Ibotenic acid is structurally similar to glutaminic acid and mimics its effects in animals. Ibotenic acid is rapidly converted to muscimol, which structurally resembles GABA" (IPCS INCHEM, PIM G026). The same pairing — ibotenic acid as a glutamate-receptor agonist, muscimol as a GABA-A agonist — is the core of the standard chemistry-and-toxicology review of the species (Michelot & Melendez-Howell, Mycological Research, 2003).
Glutamate is the brain's main excitatory transmitter. GABA is its main inhibitory one. So this mushroom is not a sedative that occasionally misbehaves — it is a mixture of an excitant and a depressant, delivered together, in a ratio nobody measured before it was eaten. A 2025 review in Toxins puts it in the same terms: ibotenic acid "exerts excitatory effects primarily via NMDA-glutamate receptor activation," while muscimol is "a tenfold more potent agonist of pre- and postsynaptic GABAA receptors and readily crosses the blood–brain barrier" (Stoeva-Grigorova et al., Toxins, 2025;17(12):570). Note the asymmetry there: the inhibitory compound is the more potent of the two, and the excitatory one is its precursor.
The Excitatory Half Is a Laboratory Lesioning Agent
This is the part consumer pages never mention, and it is the strongest single reason to stop reading "muscle twitching" as a slightly worse form of drowsiness.
Ibotenic acid is not an obscure compound. It is a standard tool in experimental neuroscience, used precisely because it kills neurons. In a 2020 historical review of excitotoxins, Coyle and Schwarcz describe how ibotenate "soon became the preferred experimental agent for producing excitotoxic neurodegeneration in the brain," producing uniform, spherical lesions of neurons at the injection site across diverse brain regions — and that its excitotoxicity is prevented by selective NMDA-receptor antagonists, which is what pins the mechanism to the NMDA receptor rather than to some other glutamate site (Coyle & Schwarcz, Frontiers in Neuroscience, 2020;14:927).
Two qualifications matter. Those experiments involve direct injection into brain tissue at chosen concentrations, not oral ingestion — route and exposure are not comparable, and nobody has shown that eating a mushroom produces lesions. And the same review notes something that cuts the other way: ibotenate's epileptogenic properties are weak compared with other excitotoxins, the proposed explanation being that it converts in the body to muscimol, which damps down the excitation it started.
That is the whole article in one sentence. The excitatory compound partly turns into its own antidote — and how much of it has already done so, before ingestion, is not fixed.
The Ratio Is Set Before You Ever Take It
Ibotenic acid decarboxylates into muscimol. That reaction is driven by drying and heating, and it has been measured directly.
Tsunoda and colleagues tracked both compounds through processing. Twelve raw samples contained 462 units of ibotenic acid against 8 units of muscimol. After three days of sun-drying: 216 units of ibotenic acid and 96 of muscimol. After eleven days: 36 and 33. Their conclusion was that drying in sun or with a heater raised muscimol despite losing ibotenic acid, and that the toxicity of the mushroom "would be intensified by processing" (Tsunoda et al., Food Hygiene and Safety Science, 1993;34(2):153–160).
Run the arithmetic those figures imply, which the paper does not do for you. Raw material was roughly 58 parts ibotenic acid to 1 part muscimol. Three days of sun-drying brought that to about 2.3 to 1. Eleven days brought it to about 1.1 to 1. Across a fortnight of ordinary drying, the excitatory-to-inhibitory ratio of the same mushrooms moved more than fiftyfold.
So "the effects of Amanita muscaria" is not a single pharmacological object. Fresh material is overwhelmingly weighted toward the glutamatergic side; thoroughly dried material is close to balanced. The Toxins review makes the same point clinically — fresh mushrooms "exhibit different toxicity compared to dried specimens, where part of the ibotenic acid is converted to muscimol" — and adds that the reverse conversion is also possible. Which symptoms someone gets is decided partly by a drying shed; our guide to what actually changes after drying, and what doesn't covers the storage side.
Why the Effects Alternate Instead of Escalating
The two-column layout predicts escalation: more dose, more of the same, worse. The case literature describes something different. The Toxins review notes that during an A. muscaria episode "the patient's condition may fluctuate between excitatory and depressive phases," which is why continuous observation is the standard advice rather than a single assessment.
That fluctuation is what two agonists with opposite signs and different time courses should produce. It also shows up in symptom frequencies: a regional poison-centre review found gastrointestinal effects, CNS depression and CNS excitation each in roughly 35% of A. muscaria cases — excitation as common as sedation, not a rare paradoxical reaction. The full numbers and their limits are in our adverse-event piece.
The IPCS timeline fits the same picture. Symptoms "appear within 30 to 90 minutes" and are "most marked at 2 or 3 hours," typically lasting around six hours but sometimes persisting for 12 to 24. The described progression runs drowsiness, then confusion, dizziness and ataxia, then euphoria or delirium, then visual and auditory disturbance and muscle effects. Read against the receptor map, that stops looking like a severity ramp and starts looking like two overlapping curves — the inhibitory one showing first, the excitatory presentation surfacing later.
One practical consequence follows, and it is the reason to know any of this. Someone who feels heavy and drowsy at 45 minutes has not seen the whole of what they took. The twitching, agitation and confusion further down the standard list are not a warning that they escalated — they are the other compound, arriving on its own schedule.
The Salivation Problem: One Symptom the Standard Mechanism Can't Explain
Now the awkward item. Increased salivation sits on nearly every side-effect list, including the one this page used to carry. It is a textbook cholinergic sign — the same family as sweating, tearing, watery eyes and a slowed heart rate — and neither ibotenic acid nor muscimol is a cholinergic drug.
The received answer has been that muscarine, the compound named after this mushroom, is present in quantities too small to matter. The IPCS monograph states it flatly: "Neither muscarinic nor atropinic effects have been observed in poisoning due to A. muscaria or A. pantherina," and it lists atropine — the standard antidote for cholinergic poisoning — as "not recommended."
That consensus has just been challenged. A 2025 paper in the International Journal of Medicinal Mushrooms notes that the "insignificant muscarine" position rests on a single 1950s measurement of 0.0003% in fresh mushrooms, and tests it four ways: surveys of 53 people reporting cholinergic symptoms after eating A. muscaria, HPLC-MS/MS analysis of samples from three of them, independently collected mushrooms, and compiled commercial analyses. Measured muscarine ran from 0.004% up to 0.043% — roughly thirteen to one hundred and forty times the consensus figure. The authors conclude that muscarine content "must be understood as a broad range, one that ranges from the insignificant up to physiologically significant levels" (Feeney, Kababick & Wise, Int J Med Mushrooms, 2025;27(7):1–15).
Treat that as one study challenging a long-standing position, not a settled overturn — it needs replication, and the survey component is self-reported. But it is the first quantitative test of an assumption unexamined for seventy years, and it predicts something the old model doesn't: that some specimens produce genuine peripheral cholinergic effects and others don't.
The practical point is that this layer is peripheral and behaves differently from the two central ones — the Toxins review notes atropine "antagonizes only peripheral muscarinic effects and does not counteract the central manifestations induced by ibotenic acid and muscimol." Three systems, three behaviours, one list. Salivation, sweating or a slow heart rate is worth naming to a clinician as its own observation rather than folding into "I feel out of it."
What a Predictable Pattern Does and Doesn't Buy You
It would be easy to over-read all this. Mechanism tells you the menu of effects and roughly the order they can appear in. It does not tell you the dose at which any of them starts. The IPCS monograph gives a threshold for central nervous system disturbance of "about 6 mg of muscimol or 30 to 600 mg of ibotenic acid" — a twenty-fold span, in purified compound, before any mushroom-to-mushroom variability is added. And a 2026 review in Frontiers in Pharmacology concludes the reported figures "do not establish a reliable dose–response relationship," with the evidence base "limited predominantly to case reports" (Ordak, Frontiers in Pharmacology, 2026;17:1838212).
So the pattern is predictable in kind and unpredictable in quantity — a combination that defeats the intuition most dosing advice runs on, as our piece on why the gram ladder is the wrong unit sets out. It also disposes of the claim that a small enough dose gives relaxation without sedation: lowering a dose changes intensity, not which receptors a molecule binds (why "relaxation without sedation" is a selectivity claim).
What the Mechanism View Changes in Practice
Four things follow from reading the list by receptor rather than by severity. None of them is a treatment instruction, and none of them makes anything safe.
- Agitation is not evidence of a bad batch. Excitation is one of the mushroom's two expected directions and appears about as often as sedation. Reading it as contamination — or as a reason to take something sedating to "balance it" — misreads the pharmacology.
- Twitching is a different signal from drowsiness, not a worse one. Muscle fasciculation and, at the severe end, seizure activity sit on the glutamatergic side. A page that lists them as the high-dose continuation of drowsiness is describing severity, not biology.
- Peripheral cholinergic signs deserve to be named separately. Salivation, sweating, tearing and heart-rate changes may belong to a third mechanism the standard two-compound story does not cover, and whose plausibility has only just been re-opened.
- GABA-A stacking is mechanistically specific, not generically cautionary. Alcohol, benzodiazepines, z-drugs, sedating antihistamines and opioid-class depressants converge on the same inhibitory system muscimol acts on. No human interaction study exists here, so the size of that overlap is unknown rather than small.
And the boundary: mechanism does not tell you when a situation has become an emergency, or what happens then. There is no antidote and management is supportive — that side is covered in our guide to recognition and emergency response, with identification basics in our fly agaric facts, risks and safe-use guide.
Frequently Asked Questions
Why does Amanita muscaria cause both stimulation and sedation?
Because it contains two compounds pointing in opposite directions. Ibotenic acid is a glutamate-receptor agonist acting largely at NMDA receptors; muscimol is a GABA-A agonist producing sedation, ataxia and amnesia. Ibotenic acid also converts into muscimol, so the two arrive on different schedules — which is why case reports describe patients fluctuating between excitatory and depressive phases rather than escalating in one direction.
Is muscle twitching just a sign of taking too much?
It is better read as a different mechanism than as a bigger dose. Muscle fasciculation, agitation and seizure activity sit on the glutamatergic side of the mushroom's chemistry; drowsiness and heavy sedation come from the GABAergic side. A list presenting twitching as the high-dose continuation of drowsiness is ordering symptoms by severity, not by the system producing them.
Does drying Amanita muscaria change which side effects it produces?
Measurably, yes. Tsunoda and colleagues found raw samples at 462 units of ibotenic acid to 8 of muscimol; after three days of sun-drying, 216 to 96; after eleven days, 36 to 33. The excitatory-to-inhibitory ratio shifts by more than fiftyfold across that range, and the authors concluded that processing intensifies rather than reduces toxicity. Fresh and dried material are not the same pharmacological object.
Why is increased salivation on the side-effect list if muscarine content is negligible?
That has been the standing puzzle. The IPCS monograph states that no muscarinic effects have been observed in A. muscaria poisoning and that atropine is not recommended. A 2025 analysis measured muscarine at 0.004% to 0.043% — far above the 1950s figure of 0.0003% the consensus rests on — and argues the content should be understood as a broad range reaching physiologically significant levels in some specimens. That is one study challenging a long-held position, and it awaits replication.
Does knowing the mechanism let you predict your own dose response?
No. Mechanism predicts the kinds of effects possible and roughly the order they can appear in; it says nothing about the amount at which they start. The IPCS threshold for central effects spans 30 to 600 mg of ibotenic acid — twenty-fold, in purified compound — and a 2026 review concluded the published figures do not establish a reliable dose–response relationship at all.
How long after ingestion do effects start, and how long do they last?
The IPCS monograph documents onset within 30 to 90 minutes, effects most marked at two to three hours, and duration usually around six hours but sometimes persisting for 12 to 24. Because two compounds with different time courses are involved, feeling little at the 45-minute mark does not indicate that the full effect has been seen.
Does this mean small doses are safe?
It does not. Nothing here establishes a safe amount; the FDA's 2024 scientific memorandum found no toxicity studies adequate to establish safe food use and no characterised human absorption or metabolism profile. Understanding the mechanism changes how symptoms are interpreted, not whether the underlying uncertainty exists.
The Bottom Line
The two-column side-effect list is not exactly wrong — those symptoms are real and documented. It is organised in a way that hides the only thing about them that is actually predictable. A. muscaria delivers an NMDA-active excitant and a GABA-A-active depressant simultaneously, in a ratio drying quietly rewrites, with a possible third peripheral cholinergic layer a 2025 measurement has just put back on the table. That structure explains why effects alternate, why agitation is as common as sedation, why fresh and dried material behave differently, and why one item on the list never fitted the standard explanation.
What it does not do is give anyone a number. A substance you can characterise but cannot dose is a harder problem than a list of mild inconveniences suggests. To see what that structure looks like when it meets real people, the adverse-event record is the next thing to read — and a whole dried Amanita muscaria cap is at least unambiguously the thing it claims to be, which is a smaller unknown rather than a safety guarantee.
Written by Viktor, who runs Amanita Store and spends more time reading toxicology monographs than is probably normal. This article is educational and is not medical advice. Amanita muscaria is not an approved food ingredient in the United States and is not a treatment for any condition. Legal status varies by jurisdiction and changes — verify locally. If you are managing anxiety, insomnia, ADHD or depression, talk to a clinician.